Altanine Announces The Appointment Of Charles J. Andres, Ph.D., J.D., As Chief Executive Officer To Lead Clinical And Strategic Expansion

Charles J. Andres, Ph.D., J.D., has been appointed as the new Chief Executive Officer of Altanine. With a strong background in intellectual property strategy, regulatory affairs, and drug discovery and development, Dr. Andres brings a wealth of experience that will support Altanine’s mission to enhance patient outcomes through innovative drug delivery technologies in high-growth therapeutic areas.

Throughout his career, Dr. Andres has led teams that have built global patent portfolios, secured patents for FDA-approved medications, and supported life science transactions and partnerships valued at over $20 billion. His expertise spans a broad range of areas including IP strategy, FDA regulatory compliance, and pharmaceutical lifecycle management.

George Hornig, Chairman of the Board of Altanine, stated, “Charlie is a visionary leader with a profound understanding of the pharmaceutical landscape. His expertise in new drug development, intellectual property, and regulatory strategy, combined with his scientific background, makes him uniquely qualified to lead Altanine as we continue to revolutionize drug delivery technologies and expand our impact across key therapeutic areas.”

Dr. Andres said in a statement, “I’m thrilled to join Altanine during this exciting phase of growth. As the company advances its clinical trial programs and accelerates pipeline development, I look forward to supporting its strategic expansion, driving innovation in drug delivery, and helping position the company for long-term success in an evolving pharmaceutical landscape.”

Before joining Altanine, Dr. Andres served as a shareholder at Greenberg Traurig, where he provided strategic counsel on intellectual property and regulatory matters to clients in the life sciences sector. Earlier in his career, he worked as a medicinal chemist at Bristol-Myers Squibb, where he was recognized with a Presidential Award for his scientific contributions.

Dr. Andres holds a Ph.D. in chemistry from the University of Virginia and a J.D. from the Columbus School of Law at the Catholic University of America. He also holds a Regulatory Affairs Certification (RAC) and is a regular speaker and author on topics related to intellectual property and FDA regulations. His leadership is expected to play a critical role in advancing Altanine’s strategic growth and its commitment to delivering proprietary drug delivery solutions that improve patient care.